glycogen synthase kinase 3β

Overview

Glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein kinase with broad roles in cell signaling, metabolism, and stress-response pathways. It is one of two closely related GSK3 isoforms and is widely studied because of its involvement in phosphorylation-dependent regulation of proteins that influence neuronal function, inflammatory signaling, and metabolic homeostasis. In biomedical research, GSK3β is often discussed as a signaling hub rather than a single-pathway enzyme, since its activity can intersect with pathways such as AMPK/mTOR, β-catenin-related signaling, and kinase networks involving PKCα.

Because of this central position, GSK3β has attracted attention as a therapeutic target in neurodegenerative disease, cancer-related signaling, and metabolic disorders. In the recent studies summarized here, it was investigated in contexts ranging from Alzheimer’s disease-related pathology, including tau and Beta amyloid-associated mechanisms, to endothelial dysfunction in Metabolic dysfunction associated steatohepatitis (MASH). These studies reinforce the view that GSK3β can influence both neuronal and vascular disease processes through phosphorylation-dependent control of downstream targets.

Focus of Latest Publications

Recent publications have examined GSK3β as a target in several disease-relevant settings, especially neurodegeneration and metabolic inflammation.

In one study focused on prion synaptotoxic pathways, a chemo-omic pipeline identified compounds that converged on three protein kinase targets: Ca2+/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), and glycogen synthase kinase 3β (GSK3β). This suggests that GSK3β may participate in a broader kinase network associated with synaptic toxicity and that pharmacologic modulation of this axis could contribute to inhibitory drug discovery.

Several Alzheimer’s disease-oriented studies also highlighted GSK3β. One report described a unique compound 3c designed to target GSK-3β and metal ions, with the goal of interfering with tau phosphorylation, metal dyshomeostasis, and amyloid-β (Aβ) accumulation. The study further reported that this compound promoted neurite outgrowth, decreased Aβ accumulation and ABTS•+ activity, and enhanced zebrafish motility. These findings position GSK3β as part of a multimodal strategy aimed at modifying multiple pathological features relevant to Alzheimer’s disease.

Another study on coumarin-based acetylcholinesterase inhibitors described compounds developed as multimodal anti-Alzheimer agents targeting acetylcholinesterase (AChE), butyrylcholinesterase, and GSK3β. In this context, GSK3β was included as a complementary target alongside cholinesterase inhibition, reflecting a design strategy intended to combine symptomatic and disease-modifying mechanisms. The mention of hippocampal neurons, neuronal cell culture model systems, and immunocytochemical staining indicates that the biological effects of these compounds were assessed in neuronal contexts relevant to cognition and neurodegeneration.

A separate investigation in metabolic disease examined endothelial cell glycogen synthase kinase 3β in the setting of MASH. The authors reported that endothelial-cell GSK3β acts as a central signaling hub in liver sinusoidal endothelial cells during MASH and that endothelial cell-specific Gsk3β knockout (Gsk3βEnd) mice were used to study its function. The study linked GSK3β to lipotoxic endotheliopathy and liver inflammation, indicating that the kinase contributes to vascular and inflammatory dysfunction in metabolic liver disease. This work broadens the relevance of GSK3β beyond the nervous system and supports its role in endothelial biology and inflammatory signaling.

Taken together, these studies portray GSK3β as a convergent target in diverse pathological processes. In neuronal disease models, it is associated with tau-related pathology, Aβ accumulation, and synaptic dysfunction; in metabolic disease, it is implicated in endothelial injury and liver inflammation. The recurring use of GSK3 inhibition across these studies underscores the therapeutic interest in modulating this kinase, either alone or in combination with other targets such as AChE, butyrylcholinesterase, PKCα, or metal-ion interactions.

Key Publications

Jun Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs. (PLoS pathogens, 2026, PMID 42313800): "These compounds converged on three protein kinase targets: Ca2+/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), and glycogen synthase kinase 3β (GSK3β)."
Mar A unique compound 3c targets GSK-3β and metal ion, interferes with tau and metal dyshomeostasis, promotes neurite outgrowth, decreases Aβ accumulation and ABTS•+, and enhances zebrafish motility. (Bioorganic chemistry, 2026, PMID 41855636): "we designed and synthesized three novel compounds targeting glycogen synthase kinase-3β (GSK-3β) and metal ion to interfere with the key pathological pathways involved in tau phosphorylation, metal dyshomeostasis, and amyloid-β (Aβ) accumulation."
Jun Development of coumarin-based acetylcholinesterase inhibitors: Synthesis, biological assessment and computational simulations. (Bioorganic chemistry, 2026, PMID 41691754): "...as multimodal anti-Alzheimer agents targeting acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and glycogen synthase kinase-3β (GSK-3β)."
May Endothelial Cell Glycogen Synthase Kinase 3β Promotes Lipotoxic Endotheliopathy and Liver Inflammation in MASH. (JCI insight, 2026, PMID 42084928): "We previously identified glycogen synthase kinase 3β (GSK3β) as a central signaling hub in LSECs during MASH."